KERREY J ROBERT sold $984K of THC

KERREY J ROBERT sold 5,638 shares of TENET HEALTHCARE CORP (THC) at an average of $174.52 ($173.12–$177.52, $0.98M total) across 5 trades on 2026-05-28.

Original reporting
SEC EDGAR · KERREY J ROBERT
Published May 30, 2026, 12:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:47 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$THC
Bearish
medium confidence
Mentioned
$THC
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$THCBearishLow
01

Why it matters

The director's sale could be interpreted as a bearish signal, but the modest size limits market reaction.

02

Market read

Primary insider sale; modest size; likely limited price impact.

03

What to watch

No pre‑arranged 10b5‑1 plan; the director may be diversifying holdings.

Relevance 5/10Novelty 5/10Timing: filed today

Background

SEC Form 4 filing discloses insider transactions; this is the first public report of the sale.

Company-level read

Ticker impact

$THCBearishMedium confidence
Context

Director Kerrey J. Robert sold $983,920 of TENET Healthcare shares on 2026-05-28, reducing his holding to 16,804 shares.

Expected impact

likely pressure as the market prices in the insider sell

Evidence & confidence

The sale is a direct open‑market transaction by a director, indicating possible concerns; however the amount (~$1 M) is modest for a mid‑cap.

Market effects

Minimal impact on healthcare sector; isolated insider transaction.

No broader regional effect.

Limited to TENET Healthcare investors.

Counterpoint

The sale may be routine portfolio rebalancing, not a signal of weakness.

Key entities

  • TENET Healthcare Corp.

    US‑listed healthcare services provider (ticker THC).

  • Kerrey J. Robert

    Director of TENET Healthcare.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HCAMed

Hospital Stocks Soared as Democrats Took Congress

HCA Healthcare (HCA) rose 10.34% to $510.70 on November 4, 2026, following Democratic gains in the U.S. election. Investors anticipate potential policy changes favoring hospitals and Medicaid insurers. Universal Health Services (UHS) and Tenet Healthcare (THC) also saw significant gains. HCA's stock is now valued at $106.68 billion, but analysts warn of potential downside risks if policy changes do not materialize.

$THCHighAI 8/10

Mizuho raises Tenet Healthcare stock price target on strong results

Mizuho increased its price target for Tenet Healthcare (NYSE:THC) to $305 from $290, citing strong quarterly results and raised 2026 EBITDA estimates. The stock trades near its 52-week high after a 49% six-month surge. Tenet reported Q3 2026 EPS of $6.64, beating estimates, and raised its full-year EBITDA outlook. Guggenheim maintained a Buy rating with a slightly lowered target of $306.

$THCMed

Tenet Healthcare Q3 Earnings Call Highlights

Tenet Healthcare (THC) reported Q3 earnings, with hospital segment showing 3.2% growth in admissions and 11% adjusted EBITDA increase. Revenue per admission rose 0.2% YoY. Exchange admissions and revenues declined 18%. Conifer transition activities contributed $147M, with $450M expected in 2026. Tenet generated $1.1B in adjusted free cash flow and repurchased 970K shares.